Page 1665 - Clinical Small Animal Internal Medicine
P. 1665
Index 1603
hypoadrenocorticism 83 autoimmune and immune‐mediated megaesophagus 558–560, 564
VetBooks.ir seizures and movement endoscopy 513, 514, 521–522 normal anatomy and
motility disorders 563–565
skin disease 1429
metabolic diseases 677, 680,
682–683
superficial necrolytic dermatitis
physiology 557
disorders 764 1492 prognosis for animals with
statistical interpretation for erythema esophageal disorders 559–560
practitioners 8–10 atopic dermatitis 1404–1406 recognition of esophageal
venomous snake bites 461 cutaneous adverse food disorders 557–558
EO see endochondrial ossification reactions 1420 strictures 478, 530, 561, 1047
eosinophilic dermatitis 1498–1500 superficial necrolytic treatment of esophageal
diagnosis 1499 dermatitis 1492 disorders 559–561
etiology/pathophysiology venomous snake bites 461 tumors of the esophagus 478–479
1498–1499 erythema multiforme (EM) 543, 543, upper gastrointestinal tract
history and clinical signs 1423–1424 radiography/esophagram
1499, 1499 erythrocytosis 1214–1215 474–475
prognosis 1499–1500 erythroderma 1499 vascular ring anomalies 476,
signalment 1499 ESBL see extended‐spectrum 477, 562
treatment 1499 beta‐lactamase essential fatty acids see polyunsaturated
eosinophilic gastritis 487, 488 Escherichia coli 1059, 1194 fatty acids
eosinophilic granuloma esophageal and stomach cancers essential thrombocytopenia 1228–1229
complex 1503–1505 1283–1286 essential tremor syndromes
diagnosis 1504 diagnosis 1284 769–770
etiology/pathophysiology 1503 epidemiology 1283 estrogen therapy 1160, 1184
history and clinical signs etiology/pathophysiology 1283 ESWL see extracorporeal shock wave
1503–1504, 1503–1504 history and clinical signs 1283–1284 lithotripsy
oral cavity and salivary glands prognosis 1285 ethylene glycol 439–440, 1092–1094
541–542, 541 signalment 1283 ETW see endotracheal wash
prognosis 1505 treatment 1284–1285 European Advisory Board on Cat
signalment 1503 esophagitis/gastroesophageal reflux Disease 956–957
treatment 1504–1505 disease 560–562 euthanasia
eosinophilic leukemia 1228–1229 endoscopy 516, 516 approach to the cancer
eosinophilic plaques 1504, 1504 gastrointestinal imaging 478 patient 1204
EPC see exocrine pancreatic cancer motility disorders 564–567 critical care setting 352
ependymomas 779 esophagoscopy 515–517, 516, end‐of‐life care 1555–1557,
EPI see exocrine pancreatic 558, 562 1560–1564
insufficiency esophageal and stomach mycobacteriosis 983–984
epibulbar melanoma 1263–1264 cancers 1284 rabies 894
epidemic curves 834–835, 835 motility disorders 565 trauma and burns 455
epidermal collarettes 1385, 1463 esophagostomy 452, 691 Eutrombicula alfreddugesi
epidermal growth factor (EGF) 1209 esophagus 1459–1460, 1500
epidermal growth factor receptor abnormalities of the excoriations 1385, 1405
(EGFR) 52 gastroesophageal junction exercise and activity
epidermal growth factor receptor 479, 479 modification 1533–1534
(EGFR) agonists 62 diagnostic approach 558–562 exercise intolerance 120–121, 264
epidermolysis bullosa acquisita disorders 557–562 exfoliative cutaneous lupus
(EBA) 1427–1428, 1427 diverticulae 516 erythematosus (ECLE)
epilepsy see seizures/epilepsy dysphagia 474 1425–1426, 1426
epiphysial growth center 1509, 1510, endoscopy 515–517, 516, 530 exhaled breath condensate
1511–1512 fistula 478 (EBC) 299
epulides 1253, 1256 foreign bodies 476–477, exocrine pancreatic cancer
equine tetanus antitoxin 968 477–478, 558, 560–562 (EPC) 1293–1295
ERG see electroretinography gastrointestinal imaging diagnosis 1293–1294
erosions 474–479, 475–478 epidemiology 1293
approach to the dermatologic generalized esophageal etiology/pathophysiology 1293
patient 1385 dilation 475–476, 475–476 history and clinical signs 1293
